Abstract: A swinging leg pendulum movement aid for walking including a pair of assisting units for a left leg and a right leg each having a drive source for applying a pulling force to an auxiliary force transmission part, a joint angle sensor for detecting a joint angle of user's hip joints, and a control member for driving the drive sources of the respective assisting units corresponding to changes in the joint angle and applying an assistance force in a forward swinging direction to the swinging leg that kicked off a ground so as to aid a pendulum movement of the swinging leg.

Abstract: A sexual stimulation device which contains a vibrating member or vertical bullet which is attached at opposite ends to two elastic rings which may be of similar size or different sizes. The top ring is designed to have the index finger inserted inside the ring. The bottom ring is designed to have a male's penis and testicles fit inside of the ring. The device is battery operated and is primarily intended to be used for external stimulation which includes a vertical bullet (also referred to as a vibration motor) having a flexible bottom ring that attaches around a male sexual organ and can be positioned by pulling the top ring. The vertical bullet vibrates at different speeds and pulses to create different stimulations against sexual organs.

Abstract: A sexual attachment device is provided with a sleeve being removably installable over a source of vibration. The sleeve includes a top end, a bottom end, opening located at the bottom end, and a cavity located at least partially within the sleeve accessible via the opening. The source of vibration can be inserted at least partially into the cavity. Vibration generated by the source of vibration is transmittable via the sleeve. The source of vibration may be an electric toothbrush. A ring is includable at the top end with a ring opening. A method is provided for providing stimulation using the sexual attachment device.

Abstract: A skin cleanser includes a surface, such as a silicone surface, with at least one textured portion for transmitting vibrational tapping to the skin. The skin cleanser includes at least one oscillating motor for generating the tapping motion to the skin. The textured portion includes touch-points or a wave that transmit the tapping motion to skin in contact with the textured portions. The touch-points may include thicker and thinner formations of the touch-points to provide firmer or softer vibrations to the skin. The touch-points are within about 0.5 to 2.5 mm in diameter. One configuration includes multiple oscillating motors configured to provide different vibration frequencies at around 50-300 Hertz and operable simultaneously.

Abstract: An oral device, or mouthpiece, for delivering a fluid to the mouth or oropharynx of a user includes an intraoral portion and an extraoral portion, which may be integrally formed. In various embodiments, the oral device may be configured with ear loops. The intraoral portion generally includes at least one outlet port through which the fluid is delivered to the oral cavity or oropharynx. A method for making an oral device is also provided.

Abstract: A package for use with a beneficial agent delivery device. The package includes at least one filling chamber having a sealed penetrable access region, at least one compartment configured to hold a content, wherein the content includes at least one of a beneficial agent or a constituent of a beneficial agent, and at least one channel connecting the at least one filling chamber in fluid communication with the at least one compartment. At least a portion of the package is resealable to contain the content.

Abstract: The package for a pharmaceutical product includes a vial and an electronic tag for obtaining information relating to the integrity of the product as assessed from an exposure of the product to physical or environmental conditions during a time span. The tag is attached at or to a constituent of the vial; or at least a portion of the tag is integrated in a constituent of the vial. The tag includes an electronics unit including a control unit, a sensor unit including at least one sensor for monitoring the physical or environmental conditions, a display unit including a display for displaying data relating to the integrity referred to as status data and a switch. The control unit is structured and configured for effecting that the display unit displays the status data in reaction to an operation of the switch. A rip strip may be bonded to the vial body.

Abstract: A storage container for a storage and delivery station for drugs is provided. The storage container includes a retainer for preventing a multiple drug portions from being delivered simultaneously. The storage container includes a housing that surrounds a receiving chamber and has a circular cylindrical section and a base surface, and a separating device disposed rotatably in the circular cylindrical section and having multiple projections and channels. Each projection has a surface, the uppermost points of the surface defining an upper receiver boundary plane. The storage container also includes a retainer with a fastening section and a retaining section, the retaining section preventing entry of the drug portions into a channel aligned with a delivery opening, and at least one cam for removing drug portions from the retaining section, the cam being movable above the upper receiver boundary plane over the retaining section.

Abstract: A system for assisting patients in sorting and dispensing medication supplies comprises a storage tray having a number of storage compartments, and a communication system to identify a medication to be provided from a pill bottle and, based upon the identification and a known regime, automatically identify which compartments of the storage tray are to be filled with the identified medication from the pill bottle and perform the filling of the storage tray. In doing so, a patient can simply open and present any number of pill bottles to the system, and then allow the system to arrange the medication in the storage tray according to the known regimen. The regimen and regimen updates are communicated to the system by means of a wired or wireless transmission to the system from a remote location (e.g. pharmacy or doctor's office), by direct user input, or by reading such information from a barcode or similar information carrier affixed to the pill bottles.

Abstract: A bottle assembly includes a container having a liquid chamber defined therein, and a vent assembly positionable substantially entirely within the liquid chamber of the container. A collar assembly generally defines a closure for the container and is releasably engageable with a neck of the container. The collar assembly and the container are configured relative to each other to enable selective configuration between a first configuration in which the vent assembly is disposed substantially entirely within the liquid chamber of the container and a second configuration in which the vent assembly is omitted from the container.

Abstract: The disclosure discloses an anti-flatulence milk bottle, which comprises a bottle body and a nipple, wherein an edge of the nipple is arranged at a bottleneck of the bottle body through a threaded cover, the threaded cover is in threaded connection with a periphery of the bottleneck, a first air returning cover and a second air returning cover are arranged between the nipple and the bottleneck, a first gap is formed between the first air returning cover and the second air returning cover, a second gap is formed between the threaded cover and an outer surface of the bottleneck, the first gap is communicated with the second gap, the first air returning cover is provided with a first opening communicated with an interior of the bottle body, and the first gap, the second gap and the first opening form a confluence passage.

Abstract: Systems and methods for monitoring nutritional uptake of an individual are disclosed. The method can include monitoring microflora intestinal gas concentration levels associated with a patient and adjusting the volume of nutrient provided by the patient with an artificial feeding device based at least in part on the microflora intestinal gas levels associated with the patient. A microflora intestinal gas sensor can be used to monitor the microflora intestinal gas associated with the patient. The microflora intestinal gas sensor can monitor the microflora intestinal gas in a patient's exhaled breath or in the patient's digestive tract. The microflora intestinal gas sensor be included as part of an enteral feeding system at the distal end or outside end of an enteral feeding tube. Systems and methods for monitoring nutritional uptake of an infant based on microflora intestinal gas levels associated with the infant are also disclosed.

Abstract: A device for refeeding bowel content of a subject configured to cover a proximal ostomy of a subject and a distal member configured to cover a distal ostomy of a subject. The device may include a bowel lumen member configured to carry bowel contents between the proximal ostomy and the distal ostomy. A method for refeeding bowel content of a subject by disposing a bowel lumen member between a proximal ostomy and distal ostomy, wherein the bowel member is configured to carry bowel contents between the proximal ostomy and the distal ostomy.

Abstract: The invention relates to a curable composition for dental use comprising polyoxymetalates and/or derivatives thereof in an amount of at least about 5 wt.-% with respect to the weight of the composition.

Abstract: Disclosed are methods of preparing stable O/W emulsions by silicic acid complexation of micron-sized oil droplets, and stable emulsions prepared by silicic acid complexation. Compositions and products comprising the emulsions are also disclosed. Emulsions may be stable over an extended period of time at room temperature.

Abstract: A composition for application to mammalian skin. The composition can include an emulsion comprising an oil phase. The oil phase can include (a) an acrylate polymer in an amount of from about 0.25 wt % to about 10 wt %, and (b) a silicone resin in an amount of from about 0.5 wt % to about 15 wt %; wherein (a) and (b) are dissolved in a non-volatile emollient oil.

Abstract: Provided is a removable tattoo ink that is composed of colored micro-particles that create permanent tissue markings, such as tattoos. The micro-particles include an inner core housing a bio-absorbable chromophore and an outer shell, which includes polystyrene sulfonate and polyallylamine hydrochloride and is designed for rupture with ultrasonic energy. The micro-particles can be implanted in the tissue of a subject, for example to create a tattoo and ruptured in situ by the application of ultrasonic energy to remove the tattoo. Also provided are methods of making the colored micro-particles.

Abstract: The present invention relates to a liquid cosmetic composition, preferably for making up and/or caring for the skin and/or the lips, comprising, in a physiologically acceptable medium, at least one fatty phase comprising: —at least one oil, which is preferably non-volatile, —at least hydrophobic silica aerogel particles, —at least one semi-crystalline polymer, —the said composition comprising less than 5% by weight of water relative to the total weight of the composition, and preferably being anhydrous.

Abstract: The present disclosure is directed to alcohol-based anti-adherent compositions that do not adhere to or attract Gram-negative and Gram-positive bacteria once it is applied to a surface and dried. The composition may include as anti-adherent agents, hydrophilic film-formers such as cellulosics, gums, acrylates, nonionic polymers, and anionic polymers. Examples of anti-adherent agents include Hydroxypropyl methylcellulose, Cellulose gum, Acacia Senegal Gum; Polyacrylate Crosspolymer-11, VP/Dimethyl-aminoethylmethacrylate/Polycarbamyl Polyglycol Ester; Acrylates/Vinyl Neodecanoate Crosspolymer, hydroxypropyl methylcellulose, Hydroxypropylcellulose, Methylcellulose, Propylene Glycol Alginate, Polyacrylate Crosspolymer-6, VP/Polycarbamyl Polyglycol Ester, Acrylates/Steareth-20 Methacrylate Copolymer; Acrylates Copolymer, and any combination thereof. The anti-adherent may be applied to surfaces using a vehicle such as a wipe.

Abstract: The sunscreen composition includes dibenzoylmethane derivative in 1 to 5% by weight of the composition, octyl-methoxycinnamate in 1 to 10% by weight of the composition and dermatologically acceptable excipients in 79 to 97% by weight of the composition containing 60-75% aqueous phase stabilised with 1-(4-methoxy-5-benzofuranyl)-3-phenyl 1, 3 propanedione (pongamol) in 0.9 to 6% by weight of the composition.

Abstract: The present invention relates to a cosmetic composition for skin moisturization that contains minerals and a quinoa extract.

Abstract: Embodiments of the disclosure provide methods and/or compositions useful for an individual in need of treatment of a cardiac-related medical condition. In particular cases, GLP-1 is employed in a ultrasound targeted microbubble destruction (UTMD) system for delivery to cardiac tissue, thereby stimulating myocardial regeneration and, in at least some cases, reversal of cardiomyopathy.

Abstract: Uniform, rigid, spherical nanoporous calcium phosphate particles that define an internal space and an amount of active agent present in the internal space are provided. Also provided are topical delivery compositions that include the active agent loaded particles, as well as methods of making the particles and topical compositions. The particles and compositions thereof find use in a variety of different applications, including active agent delivery applications.

Abstract: The present invention includes a transdermal composition which contains a pharmaceutically effective amount of a cannabinoid for delivery of the cannabinoid to the bloodstream of a user. The composition may comprise the following components: a surfactant-lecithin organogel; and a cannabinoid. The composition may also comprise an exogenous terpene. The cannabinoid is capable of diffusing from the composition into the bloodstream of the user, and may be used in methods for treating a patient suffering from a condition such as pain, nausea and emesis, convulsions, muscle spasm, inflammation, depression, and cachexia.

Abstract: A substance delivery device comprises a substrate, a plurality of dissolvable supporting structures and a plurality of carriers. The substrate attaches to a tissue. The dissolvable supporting structures are disposed on the substrate. The carriers are disposed on the dissolvable supporting structures and encapsulating substances. The present invention further provides a substance delivery method. The substance delivery device and the substance delivery method of present invention is advantageous for providing sustained release effect and rising the applicability of transdermal or transmucosal delivery techniques.

Abstract: A kit for treating a human patient with a solid tumor with a desmoplasia associated therewith having: (1) a container of and effective amount of a CCNp37 (SEQ ID No. 37), CCNp38 (SEQ ID No. 38) or a combination of CCNp37 and CCNp38 (SEQ ID Nos. 37 and 38); (2) a container of an effective amount of a chemotherapeutic agent or an immunotherapeutic agent; and (3) instructions for administering these components which can involve a pretreatment with the CCNp37 (SEQ ID No. 37), CCNp38 (SEQ ID No. 38) or a combination of CCNp37 and CCNp38 (SEQ ID Nos. 37 and 38) to a patient in need thereof.

Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.

Abstract: A high dose orodispersible dosage form of oxcarbazepine is provided. Drug-containing particles of oxcarbazepine are included within a porous bound matrix. The dosage form disperses in saliva or water in less than 15 sec and it has sufficient hardness to withstand handling and storage. It can be used to treat diseases or disorders that are therapeutically responsive to oxcarbazepine or a derivative thereof.

Abstract: A liquid composition comprising a GLP-1 agonist and/or a pharmacologically tolerable salt thereof and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, as add-on therapy with metformin and/or with long-acting insulin/insulin derivatives where appropriate.

Abstract: Disclosed is are formulations comprising a multivesicular liposome and MTX, the administration of which results in a Cmax of MTX between 5% and 50% of the Cmax of an immediate release dosage form of MTX, the duration of which lasts from about 1 to about 30 days. Also disclosed are methods of treating autoimmune diseases and cancer by administering these formulations of MTX.

Abstract: Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.

Abstract: The present invention relates to a liposomal pharmaceutical preparation containing a multivalent ionic drug, a process for the preparation of the liposomal pharmaceutical preparation, and a use thereof in the treatment of diseases, in which the liposome has a size of about 30-80 nm, and the phospholipid bilayer has a phospholipid with a Tm higher than body temperature, so that the phase transition temperature of the liposome is higher than the body temperature.

Abstract: The present invention describes a reduction type coenzyme Q10 powder, a composition thereof, and a preparation method thereof. The reduction type coenzyme Q10 powder is obtained by reacting an oxidation type coenzyme Q10 with the presence of a reducing agent, removing an organic solvent and other purities from a reaction solution after the reaction is finished to obtain an oil-soluble reduction type coenzyme Q10 liquid, and then directly performing prill formation with cold wind on an obtained reduction type coenzyme Q10 greasy substance. The obtained reduction type coenzyme Q10 powder has a lower crystallinity, and in a Cu-K[alpha] X-ray diffraction spectrum, has a strong peak at a diffraction angle 2[theta] being 18.9 DEG, and has a very strong absorption peak at a diffraction angle 2[theta] being 22.8 DEG.

Abstract: Provided herein is a polyvinyl alcohol fine particle suitable for a pharmaceutical binder for obtaining a pharmaceutical tablet of properties including good sustained release, high hardness, and excellent friability. The polyvinyl alcohol fine particle of the present invention contains 25 mol % or more of a gauche structure in polyvinyl alcohol molecules within a 0.8-nm region inside the particle from the particle surface.

Abstract: Formulations are provided for the oral administration of avanafil, a Type V phosphodiesterase inhibitor (“PDE V inhibitor”), and analogs thereof. The formulations are orally disintegrating tablets (ODTs) that rapidly dissolve or disintegrate in the oral cavity. The tablets contain an absorption enhancing composition that increases the duodenal absorption of the active agent, following transfer from the low pH environment of the stomach to the more basic pH of the duodenum. Methods for administering the active agent using the dosage forms are provided. The invention also encompasses a method of selecting components and compositions to incorporate in the formulations which will facilitate increased absorption of the active agent in the duodenum and thus serve as “absorption enhancing compositions” herein. Also provided are methods for manufacturing orally disintegrating tablets to optimize the physical properties of the dosage forms, particularly hardness and disintegration time.

Abstract: The present invention refers to pharmaceutical beclomethasone dipropionate compositions in modified-release gastro-resistant microspheres and to their oral use in the treatment of inflammatory pathologies of the intestinal tract. Said compositions in microspheres comprise: a) a core consisting of a microsphere of inert material; b) a first intermediate coating comprising beclomethasone dipropionate and at least one physiologically acceptable excipient; c) a second modified-release gastro-resistant coating. The present invention also refers to a process for obtaining said compositions.

Abstract: Nanoparticles are provided that comprise S-nitrosothiol (SNO) groups covalently bonded to the nanoparticles and/or S-nitrosothiol containing molecules encapsulated within the nanoparticles, as well as methods of making and using the nanoparticles. The invention also provides methods of preparing nanoparticles comprising Snitrosothiol (SNO) groups covalently bonded to the nanoparticles, where the methods comprise a) providing a buffer solution comprising chitosan, polyethylene glycol, nitrite, glucose, and hydrolyzed 3-mercaptopropyltrimethoxysilane (MPTS); b) adding hydrolyzed tetramethoxysilane (TMOS) to the buffer solution to produce a sol-gel; and c) lyophilizing and ball milling the sol-gel to produce nanoparticles of a desired size.

Abstract: This disclosure teaches phospholipid nanoparticle compositions of cannabinoids formed from phospholipids and simpler lipids in an unfired sequential process that encapsulate a high concentration of cannabinoids, and create standardized precision-metered dosage forms of cannabinoids; yielding an increase cannabinoid transport across hydrophobic mucosa; increase the bioavailability of the cannabinoid 2-fold to 8-fold, decrease the dose of cannabinoids 2-fold to 8-fold less than an amount of cannabinoids needed to illicit the same therapeutic effect compared to raw and non-encapsulated cannabinoids; where the nanoparticle dynamic structure reduces the adverse effects of cannabinoids; and enable safe more efficacious cannabinoid therapy.

Abstract: The invention relates to therapeutic compositions for the treatment of dry eye, more specifically to compositions comprising a TRPM8 receptor agonist ligand. Furthermore, the invention relates to therapeutic compositions for the treatment of epiphora, more specifically to compositions comprising a TRPM8 receptor antagonist.

Abstract: Stable Phytonadione compositions for parenteral administration are provided which comprise (E) isomer of phytonadione at or greater than 97% w/w as the active ingredient, and is substantially free of (Z) isomer. Said compositions are stable, sterile, and particulate-free. Further, said compositions reduce or avoid allergic reactions to benzyl alcohol and polysorbate. In some aspects, the compositions are free or substantially free of benzyl alcohol and/or reduced amounts of polysorbate. Methods of manufacture and methods of administration also provided.

Abstract: Therapeutic compositions and methods for treatment of late-onset Gaucher disease are described herein. The compositions comprise compounds having activity as pharmacological chaperones for mutant forms of the beta-glucocerebrosidase. Methods of treatment involve providing therapeutically effective amounts of such compositions to subjects in need thereof.

Abstract: Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.

Abstract: Antimicrobial compositions and related methods are disclosed. The antimicrobial compositions include glycolic acid, an anionic surfactant, and at least one additional surfactant selected from anionic and nonionic surfactants.

Abstract: Described herein are oral pharmaceutical compositions comprising liquid dosage forms of sodium naproxen in soft gel capsules. In one embodiment, the pharmaceutical composition comprises sodium naproxen, 0.2-1.0 mole equivalents of a de-ionizing agent per mole of naproxen, polyethylene glycol, and one or more solubilizers such as propylene glycol, polyvinyl pyrrolidone or a combination thereof.

Abstract: Methods of lowering the plasma LDL-C levels in a patient on a stable dose of statin where the patient has an LDL-C level above treatment goal. Methods of decreasing a patient's risk for developing coronary heart disease or having a recurrent cardiovascular event wherein the patient is on a stable dose of statin and the patient has an LDL-C level above treatment goal.

Abstract: Herein described is a topical composition for application of an NSAID, the composition comprising a solution or suspension of the NSAID as active ingredient in a residual carrier system comprising a polyhydric alcohol, a glycol ether, an ester of a higher fatty acid and water, and the ingredients of the residual carrier system have the following concentrations in percentages by weight::polyhydric alcohol 50-90%; glycol ether 7.5-40%; ester 0.5-5%; and water up to 10%. Either the composition or the residual carrier system is a single phase at ambient conditions. The composition may also comprise a volatile solvent such as ethanol or isopropyl alcohol.

Abstract: Compositions comprising a fatty acid oil mixture and at least one free fatty acid, and uses thereof are disclosed. Further disclosed are preconcentrates capable of forming a self-nanoemulsifying drug delivery system (SNEDDS), a self-microemulsifying drug delivery system (SMEDDS) or self-emulsifying drug delivery systems (SEDDS) in an aqueous solution. Preferred fatty acids are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in a form chosen from ethyl ester and triglyceride.

Abstract: The subject of the present invention is the use of aminaphtone for the preparation of a medicament for treating arteriophaties, in particular arteriophaties of a degenerative inflammatory type. Preferably, said medicament is formulated for oral administration.

Abstract: The present invention refers to novel compositions and to methods of using the compositions to treat and/or prevent obesity, obesity-related diseases or disorders (e.g., hyperglycemia, hyperinsulinemia, elevated hemoglobin A1c (HbA1c), diabetes, or cardiovascular disease), and overweight. This invention also generally relates to compositions and to methods of using the compositions to increase basal metabolic rate.

Abstract: Synergistic pharmaceutical compositions including an RNase P inhibitor and a tRNA synthetase inhibitor are provided, as well as methods for their use in treating infections. Also provided herein are methods of using the compositions to inhibit a bacterial tRNA synthetase in a cell and to decolonize bacteria on a surface.